Research graph
References from Toward adaptive therapeutic timing: integration of mechanistic pharmacology and artificial intelligence in precision dosing. Local targets link to admitted publications; unresolved targets remain external evidence.
Cystatin C-guided dosing nomogram improves target attainment for cefepime in the critically ill
10.1097/ccm.0000000000006622 · 2025 · External reference
Prediction of lacosamide concentrations to support dose optimization during pregnancy
10.1111/epi.18184 · 2025 · External reference
Usage of rabbit anti-thymocyte/anti-T-lymphocyte globulins (ATG/ATLG) for hematological malignancies in allogeneic hematopoietic cell transplantation: best practice recommendations from the EBMT practice harmonisation and guidelines committee
10.1038/s41409-025-02742-8 · 2025 · External reference
Machine learning application in a phase I clinical trial allows for the identification of clinical-biomolecular markers significantly associated with toxicity
10.1002/cpt.2511 · 2022 · External reference
First dose target attainment with extended infusion regimens of piperacillin and meropenem
10.1186/s13054-025-05445-0 · 2025 · External reference
Simulation-based optimization of sampling schedules for model-informed precision dosing of once-daily and 4-times-daily busulfan in pediatric patients
10.1097/ftd.0000000000001217 · 2024 · External reference
Drug exposure of long-acting cabotegravir and rilpivirine in older people with human immunodeficiency virus: a pharmacokinetic modeling study
10.1093/ofid/ofae171 · 2024 · External reference
Cefepime population pharmacokinetics, antibacterial target attainment, and estimated probability of neurotoxicity in critically ill patients
10.1128/aac.00309-23 · 2023 · External reference
Population pharmacokinetics of meropenem across the adult lifespan
10.1007/s40262-024-01465-1 · 2025 · External reference
Population pharmacokinetic model development of tacrolimus in pediatric and young adult patients undergoing hematopoietic cell transplantation
10.3389/fphar.2021.750672 · 2021 · External reference
Impact of obesity on brexpiprazole pharmacokinetics: proposal for improved initiation of treatment
10.1002/jcph.1947 · 2022 · External reference
Population pharmacokinetics of piperacillin in critically ill children including those undergoing continuous kidney replacement therapy
10.1016/j.cmi.2022.03.031 · 2022 · External reference
How to use meropenem in pediatric patients undergoing CKRT? Integrated meropenem pharmacokinetic model for critically ill children
10.1128/aac.01729-23 · 2024 · External reference
Steady-state drug exposure of repeated IV bolus administration for a one compartment pharmacokinetic model with sigmoidal hill elimination
10.1007/s11538-024-01375-0 · 2024 · External reference
Physiologically based pharmacokinetic modeling of vancomycin and its comparison with population pharmacokinetic model in neonates
10.1002/jcph.6126 · 2025 · External reference
Pharmacokinetic model selection for personalized infliximab dosing in IBD
10.1002/psp4.70152 · 2025 · External reference
Nonlinear mixed-effect pharmacokinetic modeling and distribution of doxycycline in healthy female donkeys after multiple intragastric dosing–preliminary investigation
10.3390/ani11072047 · 2021 · External reference
Population pharmacokinetic model of linezolid and its metabolite PNU-142300 in elderly patients
10.1093/jac/dkaf329 · 2025 · External reference
Population pharmacokinetic analysis of atomoxetine and its metabolites in children and adolescents with attention-deficit/hyperactivity disorder
10.1002/cpt.3155 · 2024 · External reference
Pharmacokinetic evaluation of aripiprazole monohydrate as a once every 2-months long-acting injectable antipsychotic for schizophrenia
10.1080/17425255.2025.2545918 · 2025 · External reference
Data-driven identification of factors that influence the quality of adverse event reports: 15-year interpretable machine learning and time-series analyses of VigiBase and QUEST
10.2196/49643 · 2024 · External reference
A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors
10.1111/cts.12963 · 2021 · External reference
Population pharmacokinetics and pharmacodynamics of cefazolin using total and unbound serum concentrations in patients with high body weight
10.1016/j.ijantimicag.2023.106751 · 2023 · External reference
The effect of polymorphisms and other biomarkers on infliximab exposure in paediatric inflammatory bowel disease: development of a population pharmacokinetic model
10.1007/s40272-024-00621-1 · 2024 · External reference
Designing drug regimens that mitigate nonadherence
10.1007/s11538-021-00976-3 · 2022 · External reference
Exposure–response efficacy modeling to support trofinetide dosing in individuals with Rett syndrome
10.1007/s12325-024-02796-y · 2024 · External reference
Reinforcement learning and PK-PD models integration to personalize the adaptive dosing protocol of erdafitinib in patients with metastatic urothelial carcinoma
10.1002/cpt.3176 · 2024 · External reference
Precision dosing in presence of multiobjective therapies by integrating reinforcement learning and PK–PD models: application to givinostat treatment of polycythemia vera
10.1002/psp4.70012 · 2025 · External reference
Pragmatic physiologically-based pharmacokinetic modeling to support clinical implementation of optimized gentamicin dosing in term neonates and infants: Proof-of-concept
10.3389/fped.2023.1288376 · 2023 · External reference
Adaptive cancer therapy in the age of generative artificial intelligence
10.1177/10732748241264704 · 2024 · External reference
Multiple model optimal sampling promotes accurate vancomycin area-under-the-curve estimation using a single sample in critically ill children
10.1097/ftd.0000000000001293 · 2025 · External reference
Bayesian forecasting for intravenous tobramycin dosing in adults with cystic fibrosis using one versus two serum concentrations in a dosing interval
10.1097/ftd.0000000000000900 · 2021 · External reference
Population pharmacokinetics of unbound cefazolin in infected hospitalized patients requiring intermittent high-flux haemodialysis: can a three-times-weekly post-dialysis dosing regimen provide optimal treatment?
10.1093/jac/dkae318 · 2024 · External reference
Ganciclovir pharmacokinetics and individualized dosing based on covariate in lung transplant recipients
10.3390/pharmaceutics14020408 · 2022 · External reference
Reinforcement learning derived chemotherapeutic schedules for robust patient-specific therapy
10.1038/s41598-021-97028-6 · 2021 · External reference
Consideration of height-based tobramycin dosing regimens for the treatment of adult cystic fibrosis pulmonary exacerbations
10.1111/bcp.15154 · 2022 · External reference
A digital twin of glimepiride for personalized and stratified diabetes treatment
10.3389/fphar.2025.1686415 · 2025 · External reference
A review of clinical applications of pharmacokinetic simulations for a 2-month long-acting injectable formulation of aripiprazole
10.1080/03007995.2025.2456014 · 2025 · External reference
Deep reinforcement learning for closed-loop blood glucose control
10.48550/arxiv.2009.09051 · 2020 · External reference
Artificial intelligence-based model for dose prediction of sertraline in adolescents: a real-world study
10.1080/17512433.2024.2304009 · 2024 · External reference
Physiologically based pharmacokinetic modeling of meropenem in preterm and term infants
10.1007/s40262-021-01046-6 · 2021 · External reference
A new chapter in pharmacology: artificial intelligence’s expanding role in pharmacokinetics, pharmacodynamics, and pharmacovigilance
10.1016/j.therap.2025.09.002 · 2025 · External reference
Concentration–response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy
10.1111/bcp.15177 · 2022 · External reference
A quantitative examination and comparison of the ability of australian gentamicin dosing guidelines to achieve target therapeutic concentrations in neonates
10.3390/antibiotics14010048 · 2025 · External reference
Applying exposure-response analysis to enhance mycophenolate mofetil dosing precision in pediatric patients with immune-mediated renal diseases by machine learning models
10.1016/j.ejps.2025.107146 · 2025 · External reference
Development and internal validation of a clinical prediction model for individualized dosing of BAY 81-8973, a full-length recombinant factor VIII, in pediatric patients with haemophilia a
10.1016/j.thromres.2023.10.009 · 2023 · External reference
Population pharmacokinetic modeling and probability of target attainment of ceftaroline in brain and soft tissues
10.1128/aac.00741-22 · 2022 · External reference
Prediction of vancomycin initial dosage using artificial intelligence models applying ensemble strategy
10.1186/s12859-022-05117-8 · 2023 · External reference
Tacrolimus population pharmacokinetic model–informed precision dosing in adult liver transplant patients
10.1007/s00210-025-03982-7 · 2025 · External reference
External evaluation of published population pharmacokinetic models of posaconazole
10.3389/fphar.2022.1005348 · 2022 · External reference
The vancomycin dosage calculator: prediction superiority and validation in a comparison of four algorithms using retrospective data from non-critical patients aged 18 to 59 years
10.5414/cp204793 · 2025 · External reference
Evaluation of neonatal and paediatric vancomycin pharmacokinetic models and the impact of maturation and serum creatinine covariates in a large multicentre data set
10.1007/s40262-022-01185-4 · 2023 · External reference
Machine learning modeling for predicting infliximab pharmacokinetics in pediatric and young adult patients with crohn disease: leveraging ensemble modeling with synthetic and real-world data
10.1097/ftd.0000000000001348 · External reference
Model-informed deep Q-networks to guide infliximab dosing in pediatric Crohn’s disease
10.1002/cpt.70118 · External reference
Population pharmacokinetics of total and unbound isavuconazole in critically ill patients: implications for adaptive dosing strategies
10.1007/s40262-023-01305-8 · 2023 · External reference
Renal function and hemoglobin independently predict levetiracetam exposure in epilepsy patients: a multifactorial regression study
10.2147/dddt.s553644 · 2025 · External reference
Alternate pembrolizumab dosing interval in advanced NSCLC with PD-L1 TPS ≥ 50%: 3 weekly compared to 6 weekly dosing
10.3390/curroncol29110685 · 2022 · External reference
Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic study
10.1128/aac.00962-23 · 2023 · External reference
Intrapulmonary pharmacokinetic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia and healthy subjects
10.1002/jcph.1986 · 2022 · External reference
An evidence-based rationale for dose de-escalation of subcutaneous atezolizumab
10.1007/s11523-024-01087-4 · 2024 · External reference
A single-centre randomised controlled trial comparing the standard method and target-controlled infusion as a method of administering cefoxitin, which is used to prevent surgical site infections in colorectal surgical patients: study protocol
10.1186/s13063-025-08716-x · 2025 · External reference
Evaluating islatravir administered via microneedle array patch for long-acting HIV pre-exposure prophylaxis using physiologically based pharmacokinetic modelling
10.1007/s13318-022-00793-6 · 2022 · External reference
Exploring population pharmacokinetic models in patients treated with vancomycin during continuous venovenous haemodiafiltration (CVVHDF)
10.1186/s13054-021-03863-4 · 2021 · External reference
Clozapine once-daily versus divided dosing regimen: a cross-sectional study in Japan
10.1097/jcp.0000000000001492 · 2022 · External reference
Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model
10.3324/haematol.2019.242289 · 2020 · External reference
Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: A population pharmacokinetic model
10.3324/haematol.2023.283685 · 2023 · External reference
Multi-pulse chronotherapeutic approaches for circadian rhythm disease management
10.1080/07420528.2025.2546008 · 2025 · External reference
A nonparametric population pharmacokinetic model of selumetinib in pediatric patients diagnosed with neurofibromatosis-I or plexiform neurofibromas
10.1002/psp4.70156 · 2026 · External reference
Timing of re-dosing based on population pharmacokinetic-pharmacodynamics target attainment analysis of cefmetazole in subjects undergoing lower gastrointestinal surgery
10.1016/j.jiac.2022.03.024 · 2022 · External reference
Impact of rabbit anti-thymocyte globulin (ATG) exposure on outcomes after ex vivo T-cell–depleted hematopoietic cell transplantation in pediatric and young adult patients
10.1016/j.jcyt.2024.01.004 · 2024 · External reference
Identifying medication use clusters with the R package tame based on dose, timing and ATC codes
10.1038/s41598-025-23345-9 · 2025 · External reference
Population pharmacokinetic and exposure–response model simulations: predicted exposure and efficacy for maintenance doses of intravenous golimumab every 6 or 8 weeks in patients with moderately to severely active rheumatoid arthritis
10.1016/j.clinthera.2022.01.015 · 2022 · External reference
Predicting individual treatment effects to determine duration of dual antiplatelet therapy after stent implantation
10.1161/jaha.124.034862 · 2024 · External reference
Precision pharmacokinetics of quetiapine: a physiologically based model incorporating liver cirrhosis and CYP3A4 polymorphisms
10.1002/jcph.70079 · 2025 · External reference
Safety and clinical outcomes of pembrolizumab standard-interval dosing versus extended-interval dosing in patients with breast cancer
10.1093/oncolo/oyaf371 · 2025 · External reference
Population pharmacokinetic simulation of varied immune globulin subcutaneous (human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naïve patients with primary immunodeficiency diseases
10.1016/j.intimp.2021.108044 · 2021 · External reference
Population pharmacokinetics and dosing regimen optimization of levetiracetam in epilepsy during pregnancy
10.1111/bcp.15572 · 2023 · External reference
Population pharmacokinetics and dose optimization of ceftazidime in critically ill children
10.3389/fphar.2024.1470350 · 2024 · External reference
Physiologically-based pharmacokinetic modeling and dosing optimization of cefotaxime in preterm and term neonates
10.1016/j.xphs.2024.03.002 · 2024 · External reference
Evaluation and application of population pharmacokinetic models for optimising linezolid treatment in non-adherence multidrug-resistant tuberculosis patients
10.1016/j.ejps.2024.106915 · 2024 · External reference
Dose, exposure, and treatment regimen of intravenous immunoglobulin G in multifocal motor neuropathy
10.3389/fneur.2024.1478419 · 2024 · External reference
Evaluation of the MeroRisk calculator, a user-friendly tool to predict the risk of meropenem target non-attainment in critically ill patients
10.3390/antibiotics10040468 · 2021 · External reference
A chronotherapeutics-applicable multi-target therapeutics based on AI: example of therapeutic hypothermia
10.1093/bib/bbac365 · 2022 · External reference
PBPK/PD modeling of nifedipine for precision medicine in pregnant women: enhancing clinical decision-making for optimal drug therapy
10.1007/s11095-023-03638-2 · 2024 · External reference
Population pharmacokinetics of tranexamic acid in Chinese population undergoing cardiac surgery with cardiopulmonary bypass
10.2147/dddt.s493485 · 2025 · External reference
Leveraging artificial intelligence in antibody-drug conjugate development: from target identification to clinical translation in oncology
10.1038/s41698-025-01159-2 · 2025 · External reference
Prediction of vancomycin plasma concentration in elderly patients based on multi-algorithm mining combined with population pharmacokinetics
10.1038/s41598-024-78558-1 · External reference
Joint use of population pharmacokinetics and machine learning for prediction of valproic acid plasma concentration in elderly epileptic patients
10.1016/j.ejps.2024.106876 · External reference
Prediction of teicoplanin plasma concentration in critically ill patients: a combination of machine learning and population pharmacokinetics
10.1093/jac/dkae292 · External reference
Restoration of nusinersen levels following treatment interruption in people with spinal muscular atrophy: simulations based on a population pharmacokinetic model
10.1007/s40263-022-00899-0 · 2022 · External reference
Deep reinforcement learning-based control of chemo-drug dose in cancer treatment
10.1016/j.cmpb.2023.107884 · 2024 · External reference
Simulations of topiramate dosage recommendations for poor compliance events
10.1007/s00228-022-03390-3 · 2022 · External reference
Population pharmacokinetic model of linezolid and probability of target attainment in patients with COVID-19-associated acute respiratory distress syndrome on veno-venous extracorporeal membrane oxygenation—a step toward correct dosing
10.3390/pharmaceutics16020253 · 2024 · External reference
Optimizing anti-PD1 immunotherapy: an overview of pharmacokinetics, biomarkers, and therapeutic drug monitoring
10.3390/cancers17193262 · 2025 · External reference
Imaging features of vessels and leakage patterns predict extended interval aflibercept dosing using ultra-widefield angiography in retinal vascular disease: findings from the PERMEATE study
10.1109/tbme.2020.3018464 · 2021 · External reference
Population pharmacokinetics of cefepime in critically ill children and young adults: model development and external validation for monte carlo simulations and model-informed precision dosing
10.1007/s40262-025-01485-5 · 2025 · External reference
Population pharmacokinetic model of ABL001/CTX-009 (anti-VEGF/DLL4) in adult cancer patients with solid tumor
10.1111/cas.16363 · 2024 · External reference
Physiologically based pharmacokinetic absorption model for pexidartinib to evaluate the impact of meal contents and intake timing on drug exposure
10.1002/cpdd.1385 · 2024 · External reference
Pentazocine pharmacodynamics in children: simulations to assess safety and effectiveness
10.1111/pan.15135 · 2025 · External reference
Tranexamic acid for trauma: optimal timing of administration based on the CRASH-2 and CRASH-3 trials
10.1093/bjs/znaf079 · 2025 · External reference
Population pharmacokinetics and pharmacodynamics of meropenem in critically ill patients: how to achieve best dosage regimen according to the clinical situation
10.1007/s13318-021-00709-w · 2021 · External reference
Population pharmacokinetic modeling and simulations to evaluate a potential dose regimen of testosterone undecanoate in hypogonadal males
10.1002/jcph.1939 · 2021 · External reference
Discrepancies between bayesian vancomycin models can affect clinical decisions in the critically ill
10.1155/2022/7011376 · 2022 · External reference
Population pharmacokinetic modeling of TV-46000, a risperidone long-acting subcutaneous antipsychotic for the treatment of patients with schizophrenia
10.1007/s40120-025-00723-z · 2025 · External reference
Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 2 diabetes
10.1111/dom.15266 · 2023 · External reference
A systematic review via text mining approaches of human and veterinary applications of photobiomodulation: focus on multiwave locked system laser therapy
10.1007/s10103-025-04572-y · 2025 · External reference
Pharmacometric and digital twin modeling for adaptive scheduling of combination therapy in advanced gastric cancer
10.1016/j.cmpb.2025.108919 · 2025 · External reference
Toward precision dosing of linezolid in critical ill patients: efficiency and risk of thrombocytopenia analysis by population PKPD modeling and simulations
10.1016/j.ejphar.2025.177777 · 2025 · External reference
Predicted pharmacokinetic interactions between hormonal contraception and single or intermittently dosed rifampicin
10.1002/jcph.2303 · 2023 · External reference
Opportunistic dried blood spot sampling validates and optimizes a pediatric population pharmacokinetic model of metronidazole
10.1128/aac.01533-23 · 2024 · External reference
Population pharmacokinetics of imipenem and target attainment of pharmacokinetic/pharmacodynamic indices in Chinese adults with febrile neutropenia and hematological malignancies
10.1007/s11096-025-01998-w · 2025 · External reference
Optimal dose of meropenem for the treatment of neonatal sepsis: dosing guideline variations and clinical practice deviations
10.1111/bcp.15308 · 2022 · External reference
Alternative dosing regimens of tislelizumab using a pharmacometrics model‐based approach
10.1111/cts.70223 · 2025 · External reference
Population pharmacokinetic modelling of remdesivir and its metabolite GS-441524 in hospitalised patients with COVID-19
10.1007/s40262-025-01496-2 · 2025 · External reference
Transdermal drug delivery systems powered by artificial intelligence
10.1002/adhm.202503030 · 2025 · External reference
Personalized hemodynamic management using reinforcement learning to prevent persistent acute kidney injury after cardiac surgery
10.1101/2025.10.23.25338698 · 2025 · External reference
Target-controlled infusion of propofol: a systematic review of recent results
10.1007/s10916-025-02187-y · 2025 · External reference
Population pharmacokinetics of pseudechis porphyriacus (red-bellied black snake) venom in snakebite patients
10.1080/15563650.2021.1896731 · 2021 · External reference
Individualized dosing algorithms for tacrolimus in kidney transplant recipients: current status and unmet needs
10.1080/17425255.2023.2250251 · 2023 · External reference
Leveraging clinical data to enhance the performance evaluation of ceftriaxone population pharmacokinetic models in children
10.1007/s40262-025-01486-4 · 2025 · External reference
Population pharmacokinetics and dose optimization of intravenous levofloxacin in hospitalized adult patients
10.1038/s41598-022-12627-1 · 2022 · External reference
Population pharmacokinetics of melphalan in a large cohort of autologous and allogeneic hematopoietic cell transplantation recipients: towards individualized dosing regimens
10.1007/s40262-021-01093-z · 2022 · External reference
Population pharmacokinetic study of benzylpenicillin in critically unwell adults
10.3390/antibiotics12040643 · 2023 · External reference
A deep-learning approach to predict bleeding risk over time in patients on extended anticoagulation therapy
10.1016/j.jtha.2024.04.005 · 2024 · External reference
Optimal dose of cefotaxime in neonates with early-onset sepsis: a developmental pharmacokinetic model-based evaluation
10.3389/fphar.2022.916253 · 2022 · External reference
Predictive performance and verification of physiologically based pharmacokinetic model of propylthiouracil
10.3389/fphar.2022.1013432 · 2022 · External reference
Precision dosing of voriconazole in immunocompromised children under 2 years: integrated machine learning and population pharmacokinetic modeling
10.3389/fphar.2025.1671652 · 2025 · External reference
Changes in the blood cyclosporine level after switching from voriconazole to isavuconazole in a patient with aplastic anemia: insights from physiologically based pharmacokinetic model simulation and the adverse event reporting system database study
10.3389/fmicb.2025.1525991 · 2025 · External reference
Predicting the effect of different folate doses on [68Ga]ga-PSMA-11 organ and tumor uptake using physiologically based pharmacokinetic modeling
10.1186/s13550-023-01008-y · 2023 · External reference
Population pharmacokinetics and dose simulation of levetiracetam in patients with epilepsy: influence of renal function and phenytoin co‐administration
10.1002/jcph.70101 · 2025 · External reference
Oral ibuprofen is more effective than intravenous ibuprofen for closure of a patent ductus arteriosus: can pharmacokinetic modeling help us to understand why?
10.1159/000526210 · 2023 · External reference
Comparison of dopamine D2 receptor occupancy profiles between risperidone ISM versus oral risperidone and monthly paliperidone palmitate based on population pharmacokinetic modelling and simulations
10.1080/17512433.2025.2594496 · 2025 · External reference
Population pharmacokinetics and dose optimization of vancomycin in critically ill children
10.1007/s13318-021-00695-z · 2021 · External reference
Optimizing phenobarbital dosing in critically ill patients with refractory and superrefractory status epilepticus using a population pharmacokinetic model
10.1111/epi.18517 · 2025 · External reference
Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: a prospective observational study
10.1111/bcp.14578 · 2021 · External reference
Use of machine learning for dosage individualization of vancomycin in neonates
10.1007/s40262-023-01265-z · 2023 · External reference
Machine learning approach in dosage individualization of isoniazid for tuberculosis
10.1007/s40262-024-01400-4 · 2024 · External reference
Population pharmacokinetic modeling of total and free ceftriaxone in critically ill children and young adults and monte carlo simulations support twice daily dosing for target attainment
10.1128/aac.01427-21 · 2022 · External reference
Model informed dosing of hydroxycholoroquine in COVID‐19 patients: learnings from the recent experience, remaining uncertainties and gaps
10.1111/bcp.14436 · 2021 · External reference
Personalizing biologic therapy in psoriasis: development, validation, and user testing of a precision-dosing dashboard
10.1016/j.jid.2025.01.031 · 2025 · External reference
Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia a: a population pharmacokinetic model
10.3324/haematol.2019.241554 · 2020 · External reference
Population pharmacokinetic modeling and dosing simulation of avalglucosidase alfa for selecting alternative dosing regimen in pediatric patients with late-onset pompe disease
10.1007/s10928-023-09874-8 · 2023 · External reference
Personalized cancer chemotherapy schedule: a numerical comparison of performance and robustness in model-based and model-free scheduling methodologies
10.48550/arxiv.1904.01200 · 2019 · External reference
Model-informed reinforcement learning for enabling precision dosing Via adaptive dosing
10.1002/cpt.3356 · 2024 · External reference
Optimizing mycophenolate therapy in renal transplant patients using machine learning and population pharmacokinetic modeling
10.3390/medsci13040235 · 2025 · External reference
Model-informed clinical development of once-every-6-month injection of paliperidone palmitate in patients with schizophrenia: a pharmacometric bridging approach (part I)
10.1007/s13318-024-00900-9 · External reference
Model-informed clinical development of 6-monthly injection of paliperidone palmitate in patients with schizophrenia: dosing strategies guided by population pharmacokinetic modeling and simulation (part II)
10.1007/s13318-024-00899-z · External reference
Pharmacokinetic model-informed precision dosing of natalizumab in multiple sclerosis
10.1002/psp4.70014 · 2025 · External reference
Getting the dose right using physiologically-based pharmacokinetic modeling: dexamethasone to prevent post-extubation stridor in children as proof of concept
10.3389/fped.2024.1416440 · 2024 · External reference
Amikacin dosing in neonates: evaluation of target attainment using a simplified and complex pharmacokinetic model-derived dosing regimen in clinical practice
10.1128/aac.01118-24 · 2025 · External reference
Integrating real-world data and machine learning: a framework to assess covariate importance in real-world use of alternative intravenous dosing regimens for atezolizumab
10.1111/cts.70077 · 2024 · External reference
Population pharmacokinetics and dosing simulations for aripiprazole 2-month ready-to-use long-acting injectable in adult patients with schizophrenia or bipolar I disorder
10.1002/cpdd.1397 · 2024 · External reference
Exposure–response analysis for aripiprazole once-monthly in patients diagnosed with bipolar I disorder
10.1002/cpdd.1580 · 2025 · External reference
Pharmacokinetics of ampicillin-sulbactam in azotemic and non-azotemic dogs
10.1111/jvp.13506 · 2025 · External reference
Prediction of prolonged opioid use after surgery in adolescents: insights from machine learning
10.1213/ane.0000000000005527 · 2021 · External reference
Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis
10.1093/bjd/ljae439 · 2025 · External reference
Tacrolimus exposure prediction using machine learning
10.1002/cpt.2123 · 2021 · External reference
Managing delayed or missed pregabalin doses in patients with focal epilepsy: a monte carlo simulation study
10.1007/s11096-023-01657-y · 2024 · External reference
Simulation of febuxostat pharmacokinetics in healthy subjects and patients with impaired kidney function using physiologically based pharmacokinetic modeling
10.1002/bdd.2325 · 2022 · External reference
Optimal STI controls for HIV patients based on an efficient deep Q learning method
10.1016/j.jtbi.2024.111914 · 2024 · External reference
Deep reinforcement learning for automated insulin delivery systems: algorithms, applications, and prospects
10.3390/ai6050087 · 2025 · External reference
Comparative assessment of pharmacokinetic parameters between HS016, an adalimumab biosimilar, and adalimumab (humira®) in healthy subjects and ankylosing spondylitis patients: population pharmacokinetic modeling
10.17219/acem/145947 · 2022 · External reference
Individualized dosing parameters for tacrolimus in the presence of voriconazole: a real-world PopPK study
10.3389/fphar.2024.1439232 · 2024 · External reference
Population pharmacokinetics of vancomycin in non-extremely preterm neonates based on real-world studies: influence of daily fluid input and diuretics
10.1128/spectrum.02274-24 · 2025 · External reference
A safe-enhanced fully closed-loop artificial pancreas controller based on deep reinforcement learning
10.1371/journal.pone.0317662 · 2025 · External reference
Physiologically based pharmacokinetic modeling of ritonavir-oxycodone drug interactions and its implication for dosing strategy
10.1016/j.ejps.2024.106697 · 2024 · External reference
Characterizing pharmacokinetic variability of topiroxostat in Chinese population: insights from a phase I randomized clinical trial
10.2174/0113892002348045241210071452 · 2025 · External reference
Liver microsomal protein content and activity in patients with hepatocellular carcinoma and cirrhosis: implications for the in vivo prediction of individual hepatic clearance
10.21037/jgo-2024-963 · 2025 · External reference
Physiologically-based pharmacokinetic modeling of natalizumab for multiple sclerosis patients to predict the withdrawal time in pregnancy and vaccine time in infants
10.1016/j.ejps.2025.107301 · 2025 · External reference
Population pharmacokinetics of subcutaneous alemtuzumab in kidney transplantation
10.1111/bcp.15608 · 2023 · External reference
